Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


27 08, 2015

BREAKING NEWS: Daratumumab pushes forward toward FDA approval

Tags: , , , , |1 Comment

Important news as the promising new immunotherapy, daratumumab, continues to move swiftly toward FDA approval. My friends at Genmab and Jannsen in the Netherlands emailed me details last evening, along with some helpful background information to review: Daratumumab is an investigational human anti-CD38 monoclonal antibody that received Breakthrough Therapy Designation from the FDA in May,

22 07, 2014

New daratumumab study enrolling newly diagnosed, older patients

Tags: , , , |5 Comments

Janssen Biotech recently announced that it's enrolling newly diagnosed multiple myeloma patients that aren't eligible for a stem cell transplant.  The majority of ineligible transplant patients are older, but younger patients that are too sick to transplant can join the study, too. Here are the details, courtesy Pharmaceutical Business Janssen to start phase III

6 05, 2014

New daratumumab study recruiting now

Tags: , , |2 Comments

Genmab, the makers of the experimental immunotherapy, daratumumab, announced plans to launch a new Phase 3 study for relapsed/refractory patients last week: Genmab Announces New Phase III Study of Daratumumab in Multiple Myeloma & Improves 2014 Financial Guidance PDF Company Announcement Second Phase III study of daratumumab in multiple myeloma Patient recruitment to start in

9 03, 2014

New daratumumab/Revlimid study recruiting now!

Tags: , , |6 Comments

There was good news on the drug development front this week.  Most myeloma experts agree that the experimental immunotherapy drug, daratumumab, is the most promising anti-myeloma drug in it's class so far.  Recruiting for a Stage 3 study is a good sign.  Here's an official press release about it: Genmab Announces Phase III Study of

14 09, 2013

Daratumumab ready for Stage 2 testing

Tags: , , , , |3 Comments

Always nice to report on a promising development.  Check-out this press release about the new rising myeloma therapy star, daratumumab, that I received last week: Genmab Announces New Study of Daratumumab in Double Refractory Myeloma Genmab Announces New Study of Daratumumab in Double Refractory Multiple Myeloma      -- After initial data read-out in Part